The University of Texas MD Anderson Cancer Center
http://www.mdanderson.org/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From The University of Texas MD Anderson Cancer Center
As Magrolimab AML Studies Chug Along, The Question Becomes How To Combine It
With an FDA hold lifted and enrollment moving quickly, physicians are looking at how to combine magrolimab with other treatments in patients with TP53-mutated AML.
Tech Transfer Roundup: Novo Nordisk Foundation, Broad Institute Team On Genomic Drivers Of Disease
$47.5m partnership between the foundation and Broad researchers will mine genetic data for insights into disease mechanisms. MD Anderson, Nuvectis each unveil multiple new tie-ups.
Tech Transfer Roundup: Mydecine, Johns Hopkins Pair Up To Study Psychedelics
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.
Tech Transfer: BMS, Evotec Partner With Four UK Universities On Translational Research Efforts
The firms hope academic research can yield first-in-class therapies and spinout companies. Also, Yale unveils research alliances with three biotechs.
Company Information
- Industry
- Academic and Research Institutions
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice